



Supplementary Figure 7: Serial dilution benchmarking of a cancer patient's cfDNA spiked into healthy donor cfDNA using a patient specific panel. (A) Detection power for a range of tumor fractions using our MRD assay. (B) Fraction of replicate dilutions detected by our MRD assay and the median detection power for those samples. (C) Tumor fraction estimation benchmarking for several replicates across a range of tumor fractions.